Wishing you a happy and hopeful new year from CTS!

Looking back at 2022, CTS has celebrated much success. One of our goals continued to be becoming a beacon for the field of translational science, fulfilling a major component of ASCPT’s strategic plan. Growth of CTS since we relaunched as an ASCPT journal in 2016 is displayed in the graph above, which bodes well for continued success of the Journal.

2022 by the numbers:

• 4.516 Impact Factor (IF)
• 626,200 downloads
• 227 articles e-published
• Articles from 24 countries
• 35 days average duration from submission to first decision

In the spirit of a 2022 review, we wanted to celebrate our most impactful contributions.  Looking forward to the 2022 IF, the three most highly cited papers* are listed below.  Substantial and impactful COVID-19 research continued to be published in CTS in 2022; thus, unsurprisingly, two of the three most highly cited articles were related to COVID-19.

• COVID-19 vaccine hesitancy: Race/ethnicity, trust, and fear by Willis et al. (cited 54 times in 2022)
• Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group by Caudle et al. (cited 49 times in 2022)
• Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects by Humeniuk et al. (cited 32 times in 2022)

IF is just one way to measure journal influence. Another important metric of impact is downloads, which also demonstrated strong results in 2022. Downloads are an obvious impact metric that measures how often journal readers take the time to download an article. CTS downloads have shown impressive growth since we relaunched as an ASCPT journal in 2016. Downloads also demonstrate the value of an Open Access journal, since there is no paywall to prospective readers. The top downloaded article was a tutorial, which is consistent with our intended positive educational impact on the field of translational science. The three most downloaded articles in CTS** were:

• Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications by Chiodin et al.
• SARS‐CoV‐2 infection as a trigger of autoimmune response by Sacchi et al.
• Precision Medicine, AI, and the Future of Personalized Health Care by Johnson et al.

In our increasingly social media-connected world, another measure of journal influence is the Altmetric score, which is a measure of the global, public attention articles garner, including through news outlets and social media. Interestingly, the Altmetric score does not include LinkedIn posts, a major social media venue for ASCPT members. The three highest Altmetric scores*** in CTS were:

• Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database by Jung et al.
• Pharmacogenomic landscape of Indian population using whole genomes by Sahana et al.
• Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science by Unni et al.

Thanks to the CTS authors and readers, ASCPT membership, and the many folks who make the Journal work – including editors, peer reviewers, as well as ASCPT and Wiley staff. CTS had another successful, impactful year on the journey to becoming a beacon of translational science. The Journal owes its success to each and every one of you.

Do you have the next IF, download, or Altmetric winner? Submit to CTS, and find out. Are you curious about the top cited, downloaded, or Altmetric-winning papers? Read them today, and join us in 2023 to help drive our vision for translational science with your submissions.

_{* Preliminary 2022 impact factor “in-window” citations (i.e., those from articles that will count toward the next IF).}

_{** Downloads are the number of downloads in 2022 for any article published since 2016.}

_{*** Altmetrics calculated through December 19, 2022associated with any article published in 2022.}

Sort by: Newest First Oldest First Most Popular Most unliked